Skip to main content
Premium Trial:

Request an Annual Quote

Co-Diagnostics Closes $5M Offering of Shares

NEW YORK – Molecular diagnostics firm Co-Diagnostics said Tuesday that it is has closed a previously announced direct offering of 3.4 million shares of common stock for a purchase price of $1.45 per share and gross proceeds of about $5.0 million.

The Salt Lake City, Utah-based company said it intends to use the net proceeds from the offering for further commercialization and expansion of its infectious disease testing, agrigenomics, and vector control verticals.

Further, it expects to use the financing to accelerate sales and technology licensing activities, for ongoing development of additional applications for its technology in markets related to liquid biopsy and NGS, and for working capital and other general corporate purposes.

HC Wainwright was the exclusive lead placement agent for the offering, and Maxim Group was the co-placement agent.

Co-Diagnostics recently expanded internationally in India and Africa.

In early Tuesday morning trading on the Nasdaq, its stock retreated about 16 percent to $2.88 per share.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.